Synlogic Stock Price Target and Analyst Ratings (NASDAQ:SYBX)

Analyst Price Target for SYBX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$11.50

▲ +202.63% Upside Potential

This price target is based on 3 analysts offering 12 month price targets for Synlogic in the last 3 months. The average price target is $11.50, with a high forecast of $13.00 and a low forecast of $10.00. The average price target represents a 202.63% upside from the last price of $3.80.

Buy

The current consensus among 3 investment analysts is to buy stock in Synlogic. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
6 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

9/4/2019

0 strong buy ratings
6 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

12/3/2019

0 strong buy ratings
5 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

3/2/2020

0 strong buy ratings
4 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

5/31/2020

0 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

8/29/2020

0 strong buy ratings
2 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

11/27/2020

0 strong buy ratings
2 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

1/26/2021

0 strong buy ratings
2 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

2/25/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
1/13/2021	Chardan Capital	Boost Price Target	Buy	$5.00 ➝ $10.00	High	i
9/18/2020	Chardan Capital	Reiterated Rating	Buy	$5.00	Medium	i
8/10/2020	HC Wainwright	Reiterated Rating	Buy		High	i Rating by Ram Selvaraju at HC Wainwright
5/22/2020	HC Wainwright	Reiterated Rating	Buy	$13.00	N/A	i Rating by Ram Selvaraju at HC Wainwright
5/10/2020	Oppenheimer	Reiterated Rating	Hold		Medium	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
3/23/2020	HC Wainwright	Reiterated Rating	Buy	$13.00	Low	i Rating by Ram Selvaraju at HC Wainwright
3/12/2020	Oppenheimer	Reiterated Rating	Hold		High	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
1/13/2020	HC Wainwright	Reiterated Rating	Buy	$13.00	High	i Rating by Ram Selvaraju at HC Wainwright
12/11/2019	HC Wainwright	Reiterated Rating	Buy	$13.00	Medium	i Rating by Ram Selvaraju at HC Wainwright
11/13/2019	Piper Jaffray Companies	Reiterated Rating	Overweight	$10.00 ➝ $7.00	High	i Rating by Edward Tenthoff at Piper Jaffray Companies
9/19/2019	Chardan Capital	Reiterated Rating	Buy		High	i Rating by G. Amusa at Chardan Capital
9/9/2019	HC Wainwright	Reiterated Rating	Buy	$13.00	High	i Rating by Ram Selvaraju at HC Wainwright
9/4/2019	Piper Jaffray Companies	Set Price Target	Buy	$10.00	Low	i Rating by Edward Tenthoff at Piper Jaffray Companies
8/21/2019	HC Wainwright	Lower Price Target	Buy	$22.00 ➝ $13.00	Medium	i Rating by Ram Selvaraju at HC Wainwright
8/21/2019	Citigroup	Downgrade	Buy ➝ Sell	$20.00 ➝ $2.00	High	i
8/20/2019	Oppenheimer	Downgrade	Outperform ➝ Market Perform		High	i
8/20/2019	Piper Jaffray Companies	Reiterated Rating	Overweight	$10.00 ➝ $20.00	High	i
8/12/2019	HC Wainwright	Reiterated Rating	Buy	$22.00	High	i Rating by Ram Selvaraju at HC Wainwright
8/9/2019	Wedbush	Reiterated Rating	Outperform	$20.00	Low	i
7/16/2019	HC Wainwright	Boost Price Target	Buy	$20.00 ➝ $22.00	High	i Rating by Ram Selvaraju at HC Wainwright
7/15/2019	Chardan Capital	Set Price Target	Buy	$25.00	High	i Rating by Taylor Feehley at Chardan Capital
7/15/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$16.00 ➝ $20.00	Low	i
6/24/2019	HC Wainwright	Reiterated Rating	Buy	$20.00	Low	i
6/12/2019	Wedbush	Reiterated Rating	Outperform	$20.00	High	i
6/12/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$15.00 ➝ $16.00	High	i
4/30/2019	Jefferies Financial Group	Initiated Coverage	Buy ➝ Buy	$18.00	High	i
4/12/2019	Chardan Capital	Set Price Target	Buy	$20.00	Medium	i Rating by Taylor Feehley at Chardan Capital
3/12/2019	Chardan Capital	Reiterated Rating	Buy	$20.00	High	i Rating by T. Feehley at Chardan Capital
2/12/2019	BTIG Research	Initiated Coverage	Buy	$22.00 ➝ $22.00	High	i
12/13/2018	Chardan Capital	Initiated Coverage	Buy ➝ Buy	$20.00	Medium	i Rating by T. Feehley at Chardan Capital
12/10/2018	HC Wainwright	Set Price Target	Buy	$20.00	High	i Rating by Ram Selvaraju at HC Wainwright
11/13/2018	HC Wainwright	Reiterated Rating	Buy	$20.00	Low	i Rating by Ram Selvaraju at HC Wainwright
11/12/2018	Oppenheimer	Set Price Target	Buy	$18.00	High	i Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
10/9/2018	HC Wainwright	Set Price Target	Buy	$20.00	Low	i Rating by Ram Selvaraju at HC Wainwright
9/7/2018	Wedbush	Reiterated Rating	Outperform		Low	i
9/5/2018	Citigroup	Boost Price Target	Buy	$26.00	High	i
8/24/2018	Citigroup	Upgrade	Neutral ➝ Buy		High	i
8/9/2018	HC Wainwright	Set Price Target	Buy	$20.00	High	i Rating by Ram Selvaraju at HC Wainwright
6/29/2018	Oppenheimer	Initiated Coverage	Outperform	$18.00	High	i
6/11/2018	HC Wainwright	Reiterated Rating	Buy	$20.00	High	i Rating by Ram Selvaraju at HC Wainwright
5/22/2018	HC Wainwright	Set Price Target	Buy	$20.00	Low	i Rating by Ram Selvaraju at HC Wainwright
5/11/2018	HC Wainwright	Set Price Target	Buy	$20.00	High	i Rating by Ram Selvaraju at HC Wainwright
4/17/2018	HC Wainwright	Reiterated Rating	Buy	$20.00	High	i Rating by Ram Selvaraju at HC Wainwright
4/9/2018	Piper Jaffray Companies	Reiterated Rating	Buy	$15.00	Low	i
4/4/2018	HC Wainwright	Set Price Target	Buy	$20.00	Low	i Rating by Ram Selvaraju at HC Wainwright
3/19/2018	HC Wainwright	Initiated Coverage	Buy ➝ Buy	$20.00	Low	i Rating by R. Selvaraju at HC Wainwright
1/29/2018	Piper Jaffray Companies	Initiated Coverage	Overweight ➝ Overweight	$16.00	High	i
11/27/2017	Wedbush	Initiated Coverage	Outperform	$20.00	Medium	i Rating by D. Nierengarten at Wedbush
9/19/2017	SVB Leerink	Initiated Coverage	Outperform ➝ Outperform	$25.00	Low	i Rating by J. Schwartz at SVB Leerink LLC
4/13/2017	Cantor Fitzgerald	Reiterated Rating	Hold	$14.00	Low	i
11/15/2016	HC Wainwright	Reiterated Rating	Hold		N/A	i Rating by shaunak deepak at HC Wainwright
9/23/2016	HC Wainwright	Downgrade	Buy ➝ Neutral	$42.00 ➝ $14.00	N/A	i Rating by S. Deepak at HC Wainwright
9/22/2016	Citigroup	Lower Price Target	Neutral	$31.50 ➝ $14.00	N/A	i
9/21/2016	SVB Leerink	Reiterated Rating	Hold ➝ Neutral	$28.00 ➝ $10.50	N/A	i
9/21/2016	Oppenheimer	Downgrade	Outperform ➝ Market Perform		N/A	i
9/21/2016	Cantor Fitzgerald	Downgrade	Buy ➝ Hold	$98.00 ➝ $14.00	N/A	i Rating by Mara Goldstein at Cantor Fitzgerald
9/12/2016	HC Wainwright	Initiated Coverage	Buy	$6.00	N/A	i Rating by S. Deepak at HC Wainwright
8/16/2016	Oppenheimer	Boost Price Target	Outperform	$49.00 ➝ $91.00	N/A	i
8/16/2016	Citigroup	Downgrade	Buy ➝ Neutral	$49.00 ➝ $31.50	N/A	i
8/15/2016	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$70.00 ➝ $28.00	N/A	i Rating by M. Schmidt at SVB Leerink LLC
5/13/2016	Cantor Fitzgerald	Reiterated Rating	Buy	$98.00	N/A	i
3/30/2016	SVB Leerink	Lower Price Target	Outperform	$98.00 ➝ $70.00	N/A	i Rating by Michael Schmidt at SVB Leerink LLC

(Data available from 2/25/2016 forward)

Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with Ginkgo Bioworks for the development of synthetic biotic medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $3.80

$3.75

$4.16

50 Day Range

MA: $3.90

$2.25

$5.05

52 Week Range

Now: $3.80

$1.35

$5.11

Volume

33,539 shs

Average Volume

1,597,615 shs

Market Capitalization

$132.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.2

Frequently Asked Questions

What sell-side analysts currently cover shares of Synlogic?

The following Wall Street sell-side analysts have issued research reports on Synlogic in the last year: Chardan Capital, HC Wainwright, Oppenheimer Holdings Inc., and Zacks Investment Research.
View the latest analyst ratings for SYBX.

What is the current price target for Synlogic?

2 Wall Street analysts have set twelve-month price targets for Synlogic in the last year. Their average twelve-month price target is $11.50, suggesting a possible upside of 202.6%. HC Wainwright has the highest price target set, predicting SYBX will reach $13.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of $10.00 for Synlogic in the next year.
View the latest price targets for SYBX.

What is the current consensus analyst rating for Synlogic?

Synlogic currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SYBX will outperform the market and that investors should add to their positions of Synlogic.
View the latest ratings for SYBX.

What other companies compete with Synlogic?

Other companies that are similar to Synlogic include Relmada Therapeutics, XBiotech, IVERIC bio, Flexion Therapeutics, Clovis Oncology, Spectrum Pharmaceuticals, Bicycle Therapeutics, Magenta Therapeutics, BeyondSpring, CorMedix, Neoleukin Therapeutics, Urovant Sciences, Syros Pharmaceuticals, Amryt Pharma and Viking Therapeutics.

How do I contact Synlogic's investor relations team?

Synlogic's physical mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company's listed phone number is 617-401-9975 and its investor relations email address is [email protected] The official website for Synlogic is www.synlogictx.com.

NASDAQ:SYBX - Synlogic Stock Price Target and Predictions

Analyst Price Target for SYBX

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Synlogic?

What is the current price target for Synlogic?

What is the current consensus analyst rating for Synlogic?

What other companies compete with Synlogic?

How do I contact Synlogic's investor relations team?